** Shares of Inhalerx surge as much as 127.3% to A$0.050, their biggest pct gain since March 2020
** Medical device maker to get up to A$38.5 mln ($25.81 mln) in funds from Clendon Biotech Capital to cover clinical trial costs
** Stock hits its highest level since late March
** Around 3.7 mln shares change hands, 72.3x the 30-day avg
** Stock up 34.5% YTD, including current session, as at 0140 GMT
($1 = 1.4916 Australian dollars)
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。